[
  {
    "ts": null,
    "headline": "A Fresh Look at Bristol Myers Squibb’s Valuation Following Its Patient Connect Expansion and Drug Discount Initiative",
    "summary": "If you have been keeping an eye on Bristol-Myers Squibb (BMY), you may have noticed recent buzz surrounding its newest move: an expansion of its direct-to-patient Patient Connect platform. The company just launched significant discounts for two of its prominent drugs, Sotyktu and Eliquis, for eligible US cash-paying patients. This is more than a small tweak to the business model and reflects Bristol-Myers Squibb’s broader efforts to adapt as the regulatory focus intensifies on drug pricing...",
    "url": "https://finnhub.io/api/news?id=c7cf8386b7e726f6fa877d2721442c6b5d633419eae59b76d54518f860f49f2f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759058313,
      "headline": "A Fresh Look at Bristol Myers Squibb’s Valuation Following Its Patient Connect Expansion and Drug Discount Initiative",
      "id": 136907565,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you have been keeping an eye on Bristol-Myers Squibb (BMY), you may have noticed recent buzz surrounding its newest move: an expansion of its direct-to-patient Patient Connect platform. The company just launched significant discounts for two of its prominent drugs, Sotyktu and Eliquis, for eligible US cash-paying patients. This is more than a small tweak to the business model and reflects Bristol-Myers Squibb’s broader efforts to adapt as the regulatory focus intensifies on drug pricing...",
      "url": "https://finnhub.io/api/news?id=c7cf8386b7e726f6fa877d2721442c6b5d633419eae59b76d54518f860f49f2f"
    }
  },
  {
    "ts": null,
    "headline": "Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs",
    "summary": "Discover 2024's top Barron's Better Bets dividend stocks poised for 23.96% average gains. See which picks offer strong income & outperformance.",
    "url": "https://finnhub.io/api/news?id=ddd46ff2d850c3ba4b011f8a4ed69c6d8522280ce4b45d1281723e9ccffb3fa5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759054205,
      "headline": "Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs",
      "id": 136906962,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522637014/image_522637014.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Discover 2024's top Barron's Better Bets dividend stocks poised for 23.96% average gains. See which picks offer strong income & outperformance.",
      "url": "https://finnhub.io/api/news?id=ddd46ff2d850c3ba4b011f8a4ed69c6d8522280ce4b45d1281723e9ccffb3fa5"
    }
  },
  {
    "ts": null,
    "headline": "Since Bad Things Are Happening To Good Stocks, This May Help (Technical Analysis)",
    "summary": "Technical analysis is more relevant than ever for investors in 2025, serving as a crucial component of risk management. Check out my investment approach here.",
    "url": "https://finnhub.io/api/news?id=1f29ac71f7eb6c07f96dcf4c5e9f0f8e5a8e284ca67faca2ceea6a05ef3660ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759046400,
      "headline": "Since Bad Things Are Happening To Good Stocks, This May Help (Technical Analysis)",
      "id": 136906535,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2227030314/image_2227030314.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Technical analysis is more relevant than ever for investors in 2025, serving as a crucial component of risk management. Check out my investment approach here.",
      "url": "https://finnhub.io/api/news?id=1f29ac71f7eb6c07f96dcf4c5e9f0f8e5a8e284ca67faca2ceea6a05ef3660ac"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Bold GLP‑1 Comeback, Dividend Safe For Now",
    "summary": "Pfizer acquires Metsera to enter the booming obesity drug market with next-gen GLP-1 therapies. Find out why PFE stock is a hold.",
    "url": "https://finnhub.io/api/news?id=eb1a03a9afdaa0d5ecccf5745dcdfb5f6c13a3da36e40decc43d09225954d1f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759039378,
      "headline": "Pfizer's Bold GLP‑1 Comeback, Dividend Safe For Now",
      "id": 136906174,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "Pfizer acquires Metsera to enter the booming obesity drug market with next-gen GLP-1 therapies. Find out why PFE stock is a hold.",
      "url": "https://finnhub.io/api/news?id=eb1a03a9afdaa0d5ecccf5745dcdfb5f6c13a3da36e40decc43d09225954d1f8"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios",
    "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Stocks to Buy Now for Passive Income. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that many consider worth investing in and holding long-term. Its history dates back to the early 1800s, shaped by decades of drug innovation and strategic mergers. Today, the company […]",
    "url": "https://finnhub.io/api/news?id=596fd6209cfc693f7356591a4e9ca8f3d738e4042e3fd93baee2ce593225f3af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759021635,
      "headline": "Why Bristol-Myers Squibb (BMY) Deserves a Spot in Passive Income Portfolios",
      "id": 136904166,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb Company (NYSE:BMY) is included among the 12 Best Stocks to Buy Now for Passive Income. Bristol-Myers Squibb Company (NYSE:BMY) is a global biopharmaceutical company that many consider worth investing in and holding long-term. Its history dates back to the early 1800s, shaped by decades of drug innovation and strategic mergers. Today, the company […]",
      "url": "https://finnhub.io/api/news?id=596fd6209cfc693f7356591a4e9ca8f3d738e4042e3fd93baee2ce593225f3af"
    }
  }
]